Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 8/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | CALCA | P06881 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580972 | 1.00 | KISS1R (0.63) | KISS1RCXCR4C5AR1IL23RGLP1R | |
| SCHEMBL29581575 | 0.94 | MC4R (0.60) | KISS1RC5AR1IL23RGLP1R | |
| SCHEMBL29580601 | 0.93 | CALCRL (0.57) | — | |
| SCHEMBL29581453 | 0.93 | CALCRL (0.57) | — | |
| SCHEMBL1371681 | 0.88 | MC4R (0.52) | KISS1RC5AR1IL23RGLP1R | |
| SCHEMBL31182780 | 0.88 | C5AR1 (0.66) | CXCR4C5AR1GLP1R | |
| SCHEMBL30432147 | 0.86 | C5AR1 (0.63) | CXCR4C5AR1GLP1RCALCA | |
| SCHEMBL31488939 | 0.86 | KISS1R (0.63) | KISS1RCXCR4C5AR1IL23R | |
| SCHEMBL31622295 | 0.86 | CXCR4 (0.64) | CXCR4C5AR1GLP1RCALCA | |
| SCHEMBL30607440 | 0.86 | NPY1R (0.65) | KISS1RCXCR4C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | MC1R, MC3R, MCHR1 | KISS1R 100/4885CXCR4 501/4885C5AR1 15/4885 |
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | MC1R, MC3R, MCHR1 | KISS1R 100/4885CXCR4 501/4885C5AR1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.